Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

Affiliations

• ¹ Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland. thomas.longval@hcuge.ch.
• ² Établissement Français du Sang (EFS), Saint-Louis Hospital, Paris, France.
• ³ Hematology Department, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France.
• ⁴ Hematology Department, Centre Hospitalier Universitaire de Bordeaux, Pessac, France.
• ⁵ Hematology Department, Gustave-Roussy, Villejuif, France.
• ⁶ Hematology Department, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France.
• ⁷ Hematology Department, Centre Hospitalier Universitaire de Besançon, Besançon, France.
• ⁸ Hematopoietic Pediatric Transplant Center, Centre Hospitalier Universitaire de Rouen, Rouen, France.
• ⁹ Établissement Français du Sang (EFS), Clermont-Ferrand, France.
• ¹⁰ Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
• ¹¹ Hematology Adolescents and Young Adults, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
• ¹² Hematology Transplant Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
• ¹³ Hematology Transplant Unit, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France. flore.sicre-de-fontbrune@aphp.fr.